MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2006020049A2
(en)
|
2004-07-15 |
2006-02-23 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2600367C
(en)
*
|
2005-03-08 |
2014-08-12 |
Boehringer Ingelheim International Gmbh |
Process for preparing macrocyclic compounds
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI387603B
(en)
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3 protease inhibitors
|
GEP20105124B
(en)
|
2005-07-25 |
2010-11-25 |
Array Biopharma Inc |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
BRPI0614242A2
(en)
*
|
2005-07-29 |
2011-03-15 |
Medivir Ab |
macrocyclic hepatitis c virus inhibitors, combination and pharmaceutical composition comprising them, as well as use and process for the preparation of said inhibitors
|
AR055395A1
(en)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ569293A
(en)
|
2005-12-23 |
2011-10-28 |
Zealand Pharma As |
Modified lysine-mimetic compounds
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
NZ574605A
(en)
|
2006-07-13 |
2011-11-25 |
Achillion Pharmaceuticals Inc |
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
*
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
ES2357494T3
(en)
*
|
2006-11-16 |
2011-04-27 |
Bristol-Myers Squibb Company |
MACROCYCLIC PEPTIDES AS INHIBITORS OF HEPATITIS C.
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
PL2468724T3
(en)
|
2006-12-21 |
2016-05-31 |
Zealand Pharma As |
Synthesis of pyrrolidine compounds
|
CA2679563A1
(en)
*
|
2007-01-08 |
2008-07-17 |
Phenomix Corporation |
Macrocyclic hepatitis c protease inhibitors
|
WO2008096002A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Tibotec Pharmaceuticals Ltd. |
Hcv inhibiting macrocyclic phosphonates and amidophosphates
|
WO2008106130A2
(en)
|
2007-02-26 |
2008-09-04 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of hcv replication
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
EP2177523A1
(en)
|
2007-05-03 |
2010-04-21 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
EP2162432A2
(en)
|
2007-06-29 |
2010-03-17 |
Gilead Sciences, Inc. |
Antiviral compounds
|
KR101596524B1
(en)
|
2007-06-29 |
2016-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
Antiviral compound
|
US20090047252A1
(en)
*
|
2007-06-29 |
2009-02-19 |
Gilead Sciences, Inc. |
Antiviral compounds
|
SE531698C2
(en)
|
2007-07-12 |
2009-07-07 |
Respiratorius Ab |
New bronchodilating a, b unsaturated amides
|
US8293705B2
(en)
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
AU2008340261C1
(en)
|
2007-12-21 |
2015-12-10 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
US9163061B2
(en)
|
2007-12-21 |
2015-10-20 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
US8309685B2
(en)
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
DK2238142T3
(en)
|
2007-12-24 |
2012-10-08 |
Janssen R & D Ireland |
Macrocyclic indoles such as hepatitis C virus inhibitors
|
MX2010010660A
(en)
*
|
2008-04-11 |
2010-10-25 |
Hoffmann La Roche |
New ruthenium complexes as catalysts for metathesis reactions.
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5529120B2
(en)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
Hepatitis C virus inhibitor
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AU2009278075B2
(en)
*
|
2008-08-07 |
2013-07-04 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(en)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
|
UA103496C2
(en)
|
2008-09-17 |
2013-10-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Combination of hcv ns3 protease inhibitor with interferon and ribavirin
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2364309B1
(en)
|
2008-12-10 |
2014-10-01 |
Achillion Pharmaceuticals, Inc. |
New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EA019295B1
(en)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Synthesis of purine nucleosides and process for preparing them
|
NZ617066A
(en)
|
2008-12-23 |
2015-02-27 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
EP2401272B1
(en)
|
2009-02-27 |
2017-01-11 |
Janssen Pharmaceuticals, Inc. |
Amorphous salt of a macrocyclic inhibitor of hcv
|
TW201040181A
(en)
|
2009-04-08 |
2010-11-16 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
ES2446971T3
(en)
|
2009-05-12 |
2014-03-11 |
Albany Molecular Research, Inc. |
Tetrahydroisoquinolines substituted with aryl, heteroaryl, and heterocycle and their use
|
MX2011011907A
(en)
|
2009-05-12 |
2012-01-20 |
Albany Molecular Res Inc |
7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4- tetrahydroisoquinoline and use thereof.
|
AU2010247735B2
(en)
|
2009-05-12 |
2015-07-16 |
Albany Molecular Research, Inc. |
Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
|
TWI576352B
(en)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
Nucleoside phosphoramidates
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
BR112012000287B8
(en)
|
2009-07-07 |
2021-05-25 |
Boehringer Ingelheim Int |
pharmaceutical composition for a hepatitis c viral protease inhibitor
|
AR077712A1
(en)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
SERINA PROTEASA MACROCICLICA INHIBITORS
|
WO2011038283A1
(en)
*
|
2009-09-28 |
2011-03-31 |
Hoffmann-La Roche Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
US8933110B2
(en)
|
2010-01-25 |
2015-01-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
CN102843909A
(en)
|
2010-01-25 |
2012-12-26 |
埃南塔制药公司 |
Hepatitis c virus inhibitors
|
AU2011235044A1
(en)
|
2010-03-31 |
2012-11-22 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
EP2552933A1
(en)
|
2010-03-31 |
2013-02-06 |
Gilead Pharmasset LLC |
Purine nucleoside phosphoramidate
|
EP2455068A1
(en)
*
|
2010-11-09 |
2012-05-23 |
F. Hoffmann-La Roche AG |
Pharmaceutical composition for treating HCV infections
|
AU2011329233A1
(en)
|
2010-11-15 |
2013-05-23 |
Abbvie Deutschland Gmbh & Co Kg |
NAMPT and ROCK inhibitors
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
CA2822556A1
(en)
|
2010-12-30 |
2012-07-05 |
Enanta Pharmaceuticals, Inc |
Macrocyclic hepatitis c serine protease inhibitors
|
PE20140039A1
(en)
|
2010-12-30 |
2014-03-01 |
Enanta Pharm Inc |
HEPATITIS C SERINE PROTEASE INHIBITORS BASED ON Phenanthridine Macrocyclics
|
TW201309690A
(en)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
AU2012382373A1
(en)
|
2012-06-12 |
2014-12-11 |
Abbvie Inc. |
Pyridinone and pyridazinone derivatives
|
MA37992B1
(en)
|
2012-10-19 |
2018-09-28 |
Bristol Myers Squibb Co |
Ns3 protease inhibitor compounds for use in the treatment of hepatitis c virus infection.
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914613B1
(en)
|
2012-11-02 |
2017-11-22 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP2914614B1
(en)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9580463B2
(en)
|
2013-03-07 |
2017-02-28 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2016515139A
(en)
|
2013-03-14 |
2016-05-26 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
A new method for producing buckwheatprevir
|
WO2014145600A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
|
EP2970192A1
(en)
|
2013-03-15 |
2016-01-20 |
Achillion Pharmaceuticals, Inc. |
Sovaprevir polymorphs and methods of manufacture thereof
|
WO2014145507A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
MX2016002185A
(en)
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds.
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
WO2018202865A1
(en)
|
2017-05-05 |
2018-11-08 |
Zealand Pharma A/S |
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
|